This guideline covers diagnosing and managing atopic eczema in children under 12. It aims to improve care for children with atopic eczema by making detailed recommendations on treatment and specialist referral. The guideline also explains how healthcare professionals should assess the effect eczema has on quality of life, in addition to its physical severity.
March 2021: For additional information on treating bacterial infections, see the NICE guideline on secondary bacterial infection of eczema and other common skin conditions: antimicrobial prescribing, which has updated some recommendations in this guideline. See update information for more details.
This guideline includes recommendations on:
- assessing severity, psychological and psychosocial wellbeing, and quality of life
- identifying and managing trigger factors
- indications for referral
Who is it for?
- Healthcare professionals
- Commissioners and providers
- Children under 12 with suspected or diagnosed atopic eczema and their families or carers
Is this guideline up to date?
We checked this guideline in February 2019 and we are updating it.
Guideline development process
This guideline was previously called atopic eczema in children: management of atopic eczema in children from birth up to the age of 12 years.
The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals and practitioners are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or the people using their service. It is not mandatory to apply the recommendations, and the guideline does not override the responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families and carers or guardian.
All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.
Local commissioners and providers of healthcare have a responsibility to enable the guideline to be applied when individual professionals and people using services wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.